Omentin-1 vs hGHRH(1-44)
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and hGHRH(1-44) (Human growth hormone-releasing hormone (1-44) amide) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Omentin-1 | hGHRH(1-44) |
|---|---|---|
| Category | Diabetes & Metabolic | Growth Hormone |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | Human growth hormone-releasing hormone (1-44) amide |
| Molecular Weight | ~35 kDa | N/A |
| Half-Life | hours | 5-15 minutes |
| Amino Acids | 313 | 44 |
| Typical Dose | No approved human dose; research use only | 0.1-1 mcg/kg |
| Route | IV|SC | Subcutaneous/IV |
| Purity | ≥98% | ≥98% |
| Studies Count | 82 | 120 |
| Research Status | Pre-clinical | Clinical Research |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
hGHRH(1-44) Benefits
- ✓physiologic GH pulse support
- ✓IGF-1 pathway stimulation
- ✓pituitary receptor mapping
- ✓endocrine research tool
Omentin-1 Dosing
not established|not established
hGHRH(1-44) Dosing
0.1-1 mcg/kg SC or IV bolus for stimulation studies|single-dose endocrine challenge with timed GH sampling|pulsatile administration in clamp/infusion experiments
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
hGHRH(1-44) Side Effects
- ⚠flushing
- ⚠headache
- ⚠transient nausea
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
hGHRH(1-44)
Human GHRH(1-44) amide has been used extensively to characterize hypothalamic control of pituitary somatotrophs and the downstream GH/IGF-1 axis. It remains a standard comparator in studies of GHRH agonism, secretion dynamics, and receptor pharmacology.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.